#OP0117 explores differences of TNFi or non-TNFi use on disease activity in a diverse population of the RISE register: Black and Asian #RA patients greater reduction of #CDAI in non-TNFi #EULAR2021 @RheumNow

#OP0127 A post-hoc analysis of two RCTs showed that continued methotrexate increases clinical response rates in patients randomized to placebo therapy who were considered as having previous insufficient response to #bDMARDs. #EULAR2021 @RheumNow https://t.co/YeEVe0uwQs

Wednesday afternoon = @eular_org recommendations. @alessia_alunno presented EULAR PtC on COVID-19 pathophysiology and immunomodulatory therapies from the Rheumatology Perspective Bottom Line: Proven efficacy in severe COVID-19 based on RCTs only dexamethason #EULAR2021 @RheumNow https://t.co/didtYEEWmq

Looking forward to the discussions in these sessions. #EULAR2021 https://t.co/GPLf4LbXLP

• https://twitter.com/FerreiraRJO/status/1400436783419101187

#OP0210 Analyses of RA patients using SRQ, DANBIO and national maternal registers: extensive anti-rheumatic treatment before and maternal disease activity during pregnancy associated with higher risk of pre term birth and small gestational age #EULAR2021 @RheumNow https://t.co/qEniF4RC0l

#OP0229 GRAPPA recommendations crisply presented by @DrLauraCoates Importantly it needs to be tailored to the patient taking amongst under comorbidities and the heterogeneity of features of the clinical presentation into account. #EULAR2021 @RheumNow https://t.co/MpZGzhq0Ic

#OP0231 BADBIR register (incl. Ustekinumab & csDMARD treated patients) 2697 PsO without PsA & 590 PsO with PsA: obesity, diabetes, hypetension and inabililty to work was more likely in Pso patients with PsA than patients with PsO alone #EULAR2021 @RheumNow

#OP0233 In SELECT-PsA1 & 2 analyses for PsA with axial involvement: 31% / 34% of the studies population: > Improvement of axial symptoms on upadacitinib across several outcomes compared to PLC! > 1new onset of uveitis on upadacitinib #EULAR2021 @RheumNow https://t.co/9YK1OYEorq

Dr. Gladman highlighted the full spectrum of #PsA in today's #EULAR2021 afternoon session. "-> All domains need to be assessed in our psa patients! -> Its interesting that we have not been able to identify genetic dispositions to particular features " @RheumNow

Does clinical response equate good #HRQoL in #SLE? Dr Gomez analysed responders in #belimumab trials and showed up to 29% pts reported poor SF-36 (esp physical aspects). Physical functioning & fatigue improved with therapy #EULAR2021 #POS0101 @RheumNow https://t.co/IU1k0UetEx

Is there a need to routinely monitor #ANA in patients treated on #TNF inhibitors? The jury👨‍⚖️is still out. Of N=211, Dr Oliveira reported 75.4% had seroconversion at median 31mths of TNFi therapy. Only 2/211 (0.9%) developed SLE (mild symptoms) #EULAR2021 #POS0204 @RheumNow https://t.co/UrFucJ9xnJ

#MachineLearning to unravel pathways associated with #SLE. Dr Morand analysed N=1760 pts from RCTs. Using deep learning algorithms, they identified novel pathways (CD4 Tcell Differentiation, Macrophage and DCs) in addition to known #IFN and #JAKSTAT #EULAR2021 #POS0351 @RheumNow https://t.co/Gc7zL8JQZe

#Interferon as biomarkers in #RMD? Dr Burska on behalf of #EULAR TF reported heterogeneity in published papers re:IFN-I pathway activation assays, hence unable to perform meta-analyses of results.They proposed Consensus Terminology for IFN #research #EULAR2021 #POS0370 @RheumNow https://t.co/lbqy2xbEyt

In a UK study of newly diagnosed #SLE (within 12 months of meeting ACR criteria), Dr Yee reported BILAG-2004 Grade A or B was predictive of damage in the median FU of 73 months. MMF use appeared to be protective #EULAR2021 #POS0705 @RheumNow https://t.co/VROqTTrzwY

Is efficacy of #voclosporin in #lupus nephritis sustained at 2 years? N=116 pts on VOC and N=100 pts on Placebo enrolled in Extension Study. Dr Saxena reported patients on VOC continued meaningful ⬇️in uPCR and stable eGFR up to 2yrs vs Placebo #EULAR2021 #POS0681 @RheumNow https://t.co/M5MX7tW2CA